Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
164 participants
OBSERVATIONAL
2017-06-01
2021-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biochemical Makers for Outcome After Pediatric out-of Hospital Cardiac Arrest
NCT03873662
Assessment of Stroke Volume and Cardiac Output in Response to Varying Heart Rates
NCT03446326
Non Invasive Neuromonitoring After Cardiac Arrest
NCT02575196
CPR Training: Video Self-Instruction Kit or Video-Only
NCT01514656
Quantitative Measurement of Cardiopulmonary Resuscitation (CPR) During In Hospital Cardiac Arrest
NCT00628693
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aim 1) Serum biomarkers of neuronal (neuron specific enolase and ubiquitin carboxy-terminal hydrolase-L1) and glial injury (S100b and glial fibrillary acidic protein) Aim 2) Regional (occipital-parietal cortex, basal ganglia, and thalamus) brain MRI (T1/T2 and diffusion-weighted imaging) and magnetic resonance spectroscopy (MRS) biomarkers of neuronal injury (N-acetyl-aspartate) and energy failure (lactate) Aim 3 will model the combination of strong serum and imaging biomarkers of brain injury with clinical variables. We will assess serum biomarkers of brain mitochondrial injury with potential for novel therapeutic targets (cardiolipin and oxidized cardiolipin) in an exploratory aim. This proposed research is innovative, because a combined panel of serum and imaging biomarkers with clinical variables to accurately classify outcome after pediatric CA will be prospectively developed and optimized. These proposed aims leverage recent pilot successes and should generate accurate and reliable models of biomarkers that markedly improve post-resuscitation clinical care in children after CA. Furthermore, these results are expected to have a positive impact in advancing neurocritical care for these children, with forthcoming development of a serum biomarker point of care test and biomarker panels that will accurately classify risk of unfavorable outcome for clinicians and researchers needing to stratify by severity of injury, to monitor response to therapy, and ultimately to assist in their rehabilitation and recovery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Child had an out of hospital CA: defined as "Cessation of cardiac mechanical activity as confirmed by the absence of signs of circulation. Includes the following rhythms: pulseless electrical activity (PEA), asystole, ventricular tachycardia, and ventricular fibrillation" without a specific duration of CA to capture the full breadth of the range of neurological outcomes
3. Children will be admitted to a pediatric or cardiac ICU
4. Children have vascular access for blood draws as part of their standard of care
5. Children have a pre-CA Pediatric Cerebral Performance Category (PCPC) score of 1-3. 6. The caregivers are required to be fluent in English but some sites may support Spanish-speaking only caregivers
Exclusion Criteria
2. Children with do not resuscitate (DNR) status
3. Child is pregnant
4. Child has an absolute or major contraindication for MRI/S (metal in the eyes, cardiac pacemakers, implanted cardioverter defibrillators, neurostimulation systems, and cochlear implants)
5. Child is undergoing brain death evaluation
6. Child has metabolic disease affecting the brain
48 Hours
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pittsburgh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ericka Fink
Associate Professor, Pediatric Critical Care Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fink EL, Clark RSB, Panigrahy A, Berger R, Wisnowski J, Bluml S, Maloney D, Rubin P, Haller T, Bayir H, Beers SR, Kochanek PM, Fabio A; POCCA Investigators. Personalising Outcomes after Child Cardiac Arrest (POCCA): design and recruitment challenges of a multicentre, observational study. BMJ Open. 2020 Oct 27;10(10):e039323. doi: 10.1136/bmjopen-2020-039323.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.